Effectiveness of 3 months of rifampicin and isoniazid chemoprophylaxis for the treatment of latent tuberculosis infection in children

Archives of Disease in Childhood

Volumn 95, Issue 8, 2010, Pages 600-602

  Bright Thomas, R ^a   Nandwani, S ^a   Smith, J ^a   Morris, J A ^b   Ormerod, L P ^a,c  

^a ROYAL BLACKBURN HOSPITAL   (United Kingdom)

^b MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^c UNIVERSITY OF CENTRAL LANCASHIRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ISONIAZID; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ARTICLE; CHILD; DATA BASE; DRUG EFFICACY; FOLLOW UP; HUMAN; INFECTION PREVENTION; LATENT TUBERCULOSIS; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REGISTRATION; SENSITIVITY ANALYSIS; TREATMENT DURATION; UNITED KINGDOM; ADOLESCENT; DRUG ADMINISTRATION; DRUG COMBINATION; INFANT; TREATMENT OUTCOME; TUBERCULOSIS;

ADOLESCENT; ANTITUBERCULAR AGENTS; CHILD; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; ENGLAND; FOLLOW-UP STUDIES; HUMANS; INFANT; ISONIAZID; LATENT TUBERCULOSIS; RIFAMPIN; TREATMENT OUTCOME; TUBERCULOSIS;

EID: 77955259798     PISSN: 00039888     EISSN: 14682044     Source Type: Journal    
DOI: 10.1136/adc.2010.182600     Document Type: Article

References (22)

1. Joint Tuberculosis Committee of the British Thoracic Society. Control and prevention of tuberculosis in Britain: an updated code of practice. Br Med J 1990;300:995-9.
2. Joint Tuberculosis Committee of the British Thoracic Society. Control and prevention of tuberculosis in the United Kingdom: code of practice 1994. Thorax 1994;49:1193-200.
3. Joint Tuberculosis Committee of the British Thoracic Society. Control and prevention of tuberculosis in the United Kingdom: code of practice 2000. Thorax 2000;55:887-901.
4. Joint Tuberculosis Committee of the British Thoracic Society. Chemotherapy and management of tuberculosis in the United Kingdom: recommendations of the Joint Tuberculosis Committee of the British Thoracic Society. Thorax 1990;45:403-8.
5. Joint Tuberculosis Committee of the British Thoracic Society. Chemotherapy and management of tuberculosis in the United Kingdom: recommendations 1998. Thorax 1998;53:536-48.
6. The National Collaborating Centre for Chronic Conditions (for NICE). Tuberculosis. Clinical diagnosis and management of tuberculosis, and measures for its prevention and control. Royal College of Physicians of London, 2006.
7. Girling DJ, Chan SL. A double-blind placebo-controlled trial of three antituberculosis chemoprophylaxis regimens in patients with silicosis in Hong Kong. Am Rev Resp Dis 1992;145:36-41.
8. Ormerod LP. Reduced incidence of tuberculosis by prophylactic chemotherapy in subjects showing strong reactions to tuberculin testing. Arch Dis Child 1987;62:1005-8.
9. Ormerod LP. Rifampicin and isoniazid prophylactic chemotherapy for tuberculosis. Arch Dis Child 1998;78:169-71.
10. Ormerod LP, Harrison JM, Wright PA. Drug resistance in Mycobacterium tuberculosis: a survey over 25 years in Blackburn. Thorax 1986;41:946-50.
11. Ormerod LP, Harrison JM, Wright PA. Drug resistance trends in Mycobacterium tuberculosis: Blackburn 1985-89. Tubercle 1990;71:283-5.
12. Ormerod LP, Green RM, Horsfi eld N, et al. Drug resistance trends in M. tuberculosis: Blackburn 1990-1999. Int J Tuberc Lung Dis 2001;5:903-5.
13. Smeija MJ, Marchetti CA, Cook DJ, et al. Isoniazid for preventing tuberculosis in non-HIV infected persons. Cochrane Database Syst Rev 1999;3:CD001363.
14. Comstock GW, Livesay VT, Woolpert SF. The prognosis of a positive tuberculin reaction in childhood and adolescence. Am J Epidemiol 1974;99:131-8.
15. Horwitz O, Wilbeck E, Erickson PA. Epidemiological basis of tuberculosis eradication. Bull WHO 1969:41;95-113.
16. Sutherland I, Svandová E, Radhakrishna S. The development of clinical tuberculosis following infection with tubercle bacilli. 1. A theoretical model for the development of clinical tuberculosis following infection, linking from data on the risk of tuberculous infection and the incidence of clinical tuberculosis in the Netherlands. Tubercle 1982;63:255-68.
17. Morán-Mendoza O, Marion SA, Elwood K, et al. Tuberculin skin test size and risk of tuberculosis development: a large population-based study in contacts. Int J Tuberc Lung Dis 2007;11:1014-20. (Pubitemid 47425030)
18. Marais BJ, Gie RP, Schaaf HS, et al. The natural history of childhood intrathoracic tuberculosis: a critical review of literature from the pre-chemotherapy era. Int J Tuberc Lung Dis 2004;8:392-402. (Pubitemid 38624845)
19. Geijo MP, Herranz CR, Vaño D, et al. Short-course isoniazid and rifampin compared with isoniazid for latent tuberculosis infection: a randomized clinical trial. Enferm Infecc Microbiol Clin 2007;25:300-4. (Pubitemid 47202767)
20. Spyridis NP, Spyridis PG, Gelesme A, et al. The effectiveness of a 9-month regimen of isoniazid alone versus 3- and 4-month regimens of isoniazid plus rifampin for treatment of latent tuberculosis infection in children: results of an 11-year randomized study. Clin Infect Dis 2007;45:715-22. (Pubitemid 47378885)
21. Ena J, Valls V. Short-course therapy with rifampin plus isoniazid, compared with standard therapy with isoniazid, for latent tuberculosis infection: a meta-analysis. Clin Infect Dis 2005;40:670-6. (Pubitemid 40381339)
22. Gray M, Ormerod LP. An economic evaluation of the use of IGRA tests in the screening of contacts and new entrants for latent TB. Thorax 2007;62 (Suppl III):S49A pA22.